Evaluating ultrasound and biomarkers for monitoring abdominal aortic aneurysm after repair
Comparación De La Eficacia Entre Biomarcadores Y Ecografía Con Contraste Frente a Angio-TC En El Seguimiento De Aneurismas De Aorta Abdominal (AAA) Tras Reparación Endovascular (EVAR)
This study is testing if using a special ultrasound and blood tests can help monitor patients with repaired abdominal aortic aneurysms more safely than the usual CT scans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Instituto de Investigacion Sanitaria La Fe Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Valencia, Valencia) |
| Trial ID | NCT06866769 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the effectiveness of contrast-enhanced ultrasound (CEUS) and biomarker analysis in monitoring patients with abdominal aortic aneurysm (AAA) who have undergone Endovascular Aneurysm Repair (EVAR). The study aims to compare these methods with the standard computed tomography angiography (CTA), which involves radiation exposure and nephrotoxic contrast agents. By measuring biomarkers and performing CEUS at various intervals, the researchers hope to establish a safer follow-up protocol that minimizes risks associated with traditional imaging techniques. The study will validate the concordance and effectiveness of CEUS and biomarkers in detecting complications such as endoleaks and aneurysm remodeling.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with abdominal aortic aneurysms who are scheduled to undergo EVAR and can provide informed consent.
Not a fit: Patients with inflammatory abdominal aortic aneurysms or those with ruptured aneurysms may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer and more effective follow-up method for patients with AAA, reducing their exposure to harmful radiation and contrast agents.
How similar studies have performed: Previous studies have shown promising results with CEUS and biomarkers in similar contexts, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with AAA under follow-up who are going to be treated with EVAR. * signed informed consent to perform CTA, CEUS and for the determination of biomarkers. Exclusion Criteria: * patients with inflammatory abdominal aortic aneurysms or ruptured aneurysm.
Where this trial is running
Valencia, Valencia
- Hospital La Fe — Valencia, Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Juan Manuel Sanchís García — Hospital Universitario La Fe
- Study coordinator: Juan Manuel Sanchís García
- Email: sanchis_juagar@gva.es
- Phone: +34 961245655
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.